Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELMONT: RT002 for Glabellar Lines
NCT02303002Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daxibotulinumtoxinA in glabellar lines, sponsored by Revance Therapeutics. Started Dec 2014; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT02303002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303002.